150 related articles for article (PubMed ID: 16581247)
1. 1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
Moret V; Laras Y; Pietrancosta N; Garino C; Quéléver G; Rolland A; Mallet B; Norreel JC; Kraus JL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3298-301. PubMed ID: 16581247
[TBL] [Abstract][Full Text] [Related]
2. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
Di Vaira M; Bazzicalupi C; Orioli P; Messori L; Bruni B; Zatta P
Inorg Chem; 2004 Jun; 43(13):3795-7. PubMed ID: 15206857
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Crouch PJ; Barnham KJ; Bush AI; White AR
Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
[TBL] [Abstract][Full Text] [Related]
4. Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report.
Ibach B; Haen E; Marienhagen J; Hajak G
Pharmacopsychiatry; 2005 Jul; 38(4):178-9. PubMed ID: 16025421
[TBL] [Abstract][Full Text] [Related]
5. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL
Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042
[TBL] [Abstract][Full Text] [Related]
6. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease.
Treiber C; Simons A; Strauss M; Hafner M; Cappai R; Bayer TA; Multhaup G
J Biol Chem; 2004 Dec; 279(50):51958-64. PubMed ID: 15465814
[TBL] [Abstract][Full Text] [Related]
7. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
8. Alteration of peripheral markers of copper homeostasis in Alzheimer's disease patients: implications in aetiology and therapy.
Rossi L; Squitti R; Calabrese L; Rotilio G; Rossini PM
J Nutr Health Aging; 2007; 11(5):408-17. PubMed ID: 17657362
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and distribution of clioquinol in golden hamsters.
Bondiolotti G; Sala M; Pollera C; Gervasoni M; Puricelli M; Ponti W; Bareggi SR
J Pharm Pharmacol; 2007 Mar; 59(3):387-93. PubMed ID: 17331342
[TBL] [Abstract][Full Text] [Related]
10. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
11. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Cui Z; Lockman PR; Atwood CS; Hsu CH; Gupte A; Allen DD; Mumper RJ
Eur J Pharm Biopharm; 2005 Feb; 59(2):263-72. PubMed ID: 15661498
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for copper in neurodegenerative diseases?
Cerpa W; Varela-Nallar L; Reyes AE; Minniti AN; Inestrosa NC
Mol Aspects Med; 2005; 26(4-5):405-20. PubMed ID: 16112188
[TBL] [Abstract][Full Text] [Related]
13. The solution structure of the copper clioquinol complex.
Pushie MJ; Nienaber KH; Summers KL; Cotelesage JJ; Ponomarenko O; Nichol HK; Pickering IJ; George GN
J Inorg Biochem; 2014 Apr; 133():50-6. PubMed ID: 24503514
[TBL] [Abstract][Full Text] [Related]
14. Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels.
Schäfer S; Pajonk FG; Multhaup G; Bayer TA
J Mol Med (Berl); 2007 Apr; 85(4):405-13. PubMed ID: 17211610
[TBL] [Abstract][Full Text] [Related]
15. The toxicology of Clioquinol.
Mao X; Schimmer AD
Toxicol Lett; 2008 Nov; 182(1-3):1-6. PubMed ID: 18812216
[TBL] [Abstract][Full Text] [Related]
16. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Mandel S; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
[TBL] [Abstract][Full Text] [Related]
17. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
[TBL] [Abstract][Full Text] [Related]
18. Current status of metals as therapeutic targets in Alzheimer's disease.
Finefrock AE; Bush AI; Doraiswamy PM
J Am Geriatr Soc; 2003 Aug; 51(8):1143-8. PubMed ID: 12890080
[TBL] [Abstract][Full Text] [Related]
19. Can tetrathiomolybdate be a potential agent against Alzheimer disease? A hypothesis based on abnormal copper homeostasis in brain.
Sabayan B; Farshchi S; Zamiri N; Sabayan B
Alzheimer Dis Assoc Disord; 2010; 24(3):309-10. PubMed ID: 20798613
[No Abstract] [Full Text] [Related]
20. Metal chelator decreases Alzheimer beta-amyloid plaques.
Gouras GK; Beal MF
Neuron; 2001 Jun; 30(3):641-2. PubMed ID: 11430794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
